Immunogenicity after CoronaVac vaccination
Yükleniyor...
Dosyalar
Tarih
2021
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Associacao Medica Brasileira
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
OBJECTIVE: This study aimed to investigate the seropositivity of CoronaVac-SinoVac vaccination in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) risk factors and comorbidities. METHODS: Immunoglobulin (IgG) antibody responses were examined on the 21st day after the second dose of CoronaVac-SinoVac 6 ?g vaccine on the 28th day. SARS-CoV-2 IgG antibody levels were measured by using the enzyme-linked immunosorbent assay method in vaccinated health care workers (n=134) (Group I), vaccinated polymerase chain reaction (PCR) (+) who had coronavirus-19 (COVID-19) disease (n=21) (Group II), and unvaccinated PCR (+) (n=28) (Group III) participants. Subgroups were formed in Group I according to the presence of COVID-19 risk factors and comorbidities (diabetes mellitus, cardiovascular disease, and asthma/allergy) and demographic data. RESULTS: Seropositivity rates were 95.5, 100, and 89.3% for Groups I, II, and III, respectively. IgG antibody levels were found significantly higher in the group between the ages of 20–30 in group I compared to those aged 31–50 and over 50 (both p<0.01). It was found significantly higher in normal-weight individuals than in the overweight and obese group (both p<0.01). IgG antibody levels were found significantly lower in people with cardiovascular disease and diabetes mellitus compared with those who did not (p<0.05 and p<0.001, respectively). There was a negative correlation between IgG antibody response values and body mass index and age in Group I (r= -0.336, p<0.001 and r= -0.307, p<0.001, respectively). CONCLUSION: IgG antibody values decrease with age and with increasing body mass index. The presence of comorbidities (i.e., diabetes mellitus and cardiovascular disease) decreased COVID-19 IgG antibody values. © 2021 Associacao Medica Brasileira. All rights reserved.
Açıklama
Anahtar Kelimeler
Comorbidity, COVID-19 virus disease, Immunogenicity, Risk factors, Vaccine, coronavac, immunoglobulin G antibody, virus antibody, adult, age, antibody blood level, antibody response, Article, asthma, body mass, cardiovascular disease, comorbidity, comparative effectiveness, controlled study, coronavirus disease 2019, demography, diabetes mellitus, enzyme linked immunosorbent assay, female, health care personnel, human, major clinical study, male, outcome assessment, polymerase chain reaction, prospective study, risk factor, Severe acute respiratory syndrome coronavirus 2, treatment outcome, vaccination, vaccine immunogenicity, young adult, Adult, Antibodies, Viral, COVID-19, COVID-19 Vaccines, Humans, SARS-CoV-2, Vaccination, Young Adult
Kaynak
Revista da Associacao Medica Brasileira
WoS Q Değeri
Q3
Scopus Q Değeri
Q3
Cilt
67
Sayı
10
